Status of Platanthera praeclara Sheviak & Bowles (Western Prairie Fringed Orchid) in the Platte River Valley in Nebraska from Hamilton to Garden Counties

During June and July, 1991, a search for western prairie fringed orchid was conducted in the Platte River Valley in central and west-central Nebraska. No orchids were found in the 370 sites surveyed. Factors which may contribute to the scarcity of this orchid in the area surveyed include drought conditions in the previous three years; habitat alteration by draining, ditching, herbicide application, mowing for hay, crop cultivation and planting of non-native species for hay fields; invasion of the area by trees; and the presence of alkaline soils in some area

Mottled Duck in Nebraska

The two major US populations of Mottled Duck occur in Florida and along the Gulf Coast in Louisiana and Texas, with local breeding inland to “southeast Colorado, western Kansas, Oklahoma (rarely), and northeast Texas” (AOU Checklist of North American Birds, Sixth Edition, 1983). Palmer (Handbook of North American Birds, Vol. 2, 1976) notes that Mottled Duck bred in 1963 at Cheyenne Bottoms, Kansas, and that some individuals occur inland beyond the usual breeding range during the post-breeding period. Presumably these inland. records pertain to birds from the Texas-Louisiana population, as the Florida birds are generally considered nonmigratory. Thus the occurrence of Mottled Duck in Nebraska is a possibility, especially in the fall

The Red-Naped Sapsucker in Nebraska

The Red-naped Sapsucker (Sphyrapicus nuchalis) was for many years accorded subspecific status within Yellow-bellied Sapsucker (Sphyapicus varius), but the American Ornithologists’ Union recently revised this opinion, and now regards nuchalis as a “good” species (Auk 102:680). Red-naped Sapsucker can be added to the Nebraska (species) list on the basis of three specimens in the collection of the University of Nebraska State Museum (UNSM). The breeding range of Red-naped Sapsucker includes the Rocky Mountains east of the Cascades from southwest Canada south to central Arizona and it winters in much of northern Mexico, north as far as the southern part of its breeding range (The NOU Checklist of North American Birds, Sixth Edition, 1983)

Hybrid Bluebirds in the Pine Ridge

A hybrid pair of bluebirds is raising young in Dawes County, Nebraska, in the yard of Jim and Hope Minyard, approximately 8 miles south of Crawford. The female of the pair is a Mountain Bluebird (Sialia currucoides). She is basically a dull gray bluebird, with little contrast between upperparts and underparts. There is no rusty or tan on her breast, and no sharp demarcation between the gray breast and the lighter belly. Her rump and the bases of her outer tail feathers are a light, bright blue, while the other tail feathers and the primaries are blackish. When the wing is folded, her longest wing feathers approach, but do not reach, the tip of her tail. The male presents a more complicated picture. Superficially he resembles an Eastern Bluebird (Sialia sialis) because the upper parts are uniformly bright blue, the breast and throat are rusty, and the belly is white. The blue of his upperparts appears a lighter, more cerulean blue than is typical of Eastern Bluebirds, though it is difficult to judge without direct breast comparison. The rusty breast is paler and duller than usual for male Easterns as well. Most peculiarly, there is a small, bright blue bib or necklace on the upper breast, similar in color to the back. When folded, the male’s wing tips reach a little over half way down the tail. In other words, his wings are relatively shorter than those of the female. We believe that the male is a Mountain x Eastern Bluebird hybrid

The Red-Naped Sapsucker in Nebraska

The Red-naped Sapsucker (Sphyrapicus nuchalis) was for many years accorded subspecific status within Yellow-bellied Sapsucker (Sphyapicus varius), but the American Ornithologists’ Union recently revised this opinion, and now regards nuchalis as a “good” species (Auk 102:680). Red-naped Sapsucker can be added to the Nebraska (species) list on the basis of three specimens in the collection of the University of Nebraska State Museum (UNSM). The breeding range of Red-naped Sapsucker includes the Rocky Mountains east of the Cascades from southwest Canada south to central Arizona and it winters in much of northern Mexico, north as far as the southern part of its breeding range (The NOU Checklist of North American Birds, Sixth Edition, 1983)

Notes--\u3ci\u3eNebraska Bird Review\u3c/i\u3e (March 1982)

Notes contain stories of Cattle Egrets viewed on Prairie Dog Waterfowl Production Area near Axtell; Wood Duck broods on Carter Lake in Omaha; a first-year Thayer’s Gull on Lake North near Columbus; a variety of birds (Swamp Sparrow, Great Horned Owl, Cliff Swallows, Savannah Sparrows, Grasshopper Sparrows, Purple Martins, Carolina Wren, Great Blue Heron, Western Kingbird, Prairie Chicken, Sprague’s Pipits, and more) seen in and around the Minden area; and a Scissor-tailed Flycatcher at Verdon Lake in Richardson County

Barriers to CPR initiation and continuation during the emergency call relating to out-of-hospital cardiac arrest: A descriptive cohort study

Aim: To describe the barriers to cardiopulmonary resuscitation (CPR) initiation and continuation in emergency calls for out-of-hospital cardiac arrest (OHCA). Methods: We analysed 295 consecutive emergency calls relating to OHCA over a four-month period (1 January – 30 April 2021). Calls included were paramedic-confirmed, non-traumatic, non-EMS-witnessed OHCA, where the caller was with the patient. Calls were listened to in full and coded in terms of barriers to CPR initiation and continuation, and patient and caller characteristics. Results: Overall, CPR was performed in 69% of calls and, in 85% of these, callers continued performing CPR until EMS arrival. Nearly all callers (99%) experienced barriers to CPR initiation and/or continuation during the call. The barriers identified were classified into eight categories: reluc tance, appropriateness, emotion, bystander physical ability, patient access, leaving the scene, communication failure, caller actions and call-taker instructions. Of these, bystander physical ability was the most prevalent barrier to both CPR initiation and continuation, occurring in 191 (65%) calls, followed by communication failure which occurred in 160 (54%) calls. Callers stopping or interrupting CPR performance due to being fatigued was lower than expected (n = 54, 26% of callers who performed CPR). Barriers to CPR initiation that related to bystander physical ability, caller actions, communication failure, emotion, leaving the scene, patient access, procedural barriers, and reluctance were mostly overcome by the caller (i.e., CPR was performed). Conclusion: Barriers to CPR initiation and continuation were commonly experienced by callers, however they were frequently overcome. Future research should investigate the strategies that were successful

Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus

Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory infection in young children. RSV disease severity is known to be age-dependent and highest in young infants, but other correlates of severity, particularly the presence of additional respiratory pathogens, are less well understood. In this study, nasopharyngeal swabs were collected from two cohorts of RSV-positive infants 100 pathogens, including all common respiratory viruses and bacteria, from samples collected from 433 infants, that burden of additional viruses is common (111/433, 26%) but only modestly correlates with RSV disease severity. In contrast, there is strong evidence in both cohorts and across age groups that presence of Haemophilus bacteria (194/433, 45%) is associated with higher severity, including much higher rates of hospitalisation (odds ratio 4.25, 95% CI 2.03–9.31). There is no evidence for association between higher severity and other detected bacteria, and no difference in severity between RSV genotypes. Our findings reveal the genomic diversity of additional pathogens during RSV infection in infants, and provide an evidence base for future causal investigations of the impact of co-infection on RSV disease severity

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication